Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2.

Marzo-Ortega, Helena   •   Sieper, Joachim   •   Kivitz, Alan   •   Blanco, Ricardo   •   Cohen, Martin   •   Delicha, Evie-Maria   •   Rohrer, Susanne   •   Richards, Hanno

published in: RMD open